JINTROPIN HGH

Name:  JINTROPIN HGH

Form:  Freeze dried powder

Dosage:  10 IU/vial

Top color: Usually Black / blue / green / golden. 

Inventory: 10000 vials for sell.

MOQ: 100 vials

Package:  10vials/kit. 10kits/bag/carton 

Pack material: Shockproof film, shockproof envelope, and Cartons.  

Logo:  with or without both ok. 

OEM: Offer OEM service. Customed dosage & brand & LOGO & package & top color. OEM MOQ 100kits (=1000vials=10000ius)

Shipment: By express to buyers’ door. 100% make sure delivery. 

Payment: TT/ Western Union/BTC/ETV/VISA and so on, please contact by email. 

Shipment time: Within three working days after payment. Usually need ten days to arrive buyers’ address. Resend if lost.

DESCRIPTION

Jintropin is one of the most potent recombinant Human Growth Hormones on the market today. It is a proper 191 amino acid sequence Somatropin (natural to human body) and is produced by GeneScience Pharmaceutical Co, Ltd.

According to IMS, an internationally recognized marketing firm, Jintropin is the absolute market leader in China with just over 75% of market share. It was first introduced in 1997 when it was the first somatropin brand produced in China.

Jintropin stimulates linear cell growth and increases growth rate in children who lack adequate endogenous growth hormone. In adults with growth hormone deficiency, JINTROPIN improves metabolism which in effect reduces body’s fat storage, raises energy levels, increases muscle mass, vitality and overall well-being.

Jintropin is indicated for patients suffering from severe burns, or recovering after major operation. It is given to AIDS patients to prevent muscle wasting. Children with stunted growth, caused by various illnesses will benefit from growth hormone the most.

Recreational use of growth hormone has been on the rise ever since synthetic variant first came on the 2 decades ago. Bodybuilders brought a lot of publicity to JINTROPIN as it was their favourite brand due to the low price, high quality and availability on the black market. In 2007, when actor Sylvester Stallone was caught with Jintropin by Australian customs, the media attention finally brought trouble to the manufacturer Genescience Pharmaceuticals. Chinese government temporarily revoked Gensci’s licence while charges against the CEO of the company, Mr Jin Lei were brought up in court (Providence, United States). Gensci’s operations have since returned to normal, however Jintropin disappeared from the black market to be replaced by its successor Hypertropin. Nowadays majority of Jintropin on the black market is considered to be counterfeit.

Jintropin is created using secretion technology. Genetically modified E.coli bacteria secrete human body’s identical somatropin which is then isolated and freeze dried. This method produces a very stable form of a molecule, which is otherwise too fragile to survive room temperatures or shaking. When freeze dried it remains stable at 37C (98F degrees) for over 30 days or 45C degrees for over a week.

Side effects of Jintropin

Depending on the dosage and each individual’s response to growth hormone treatment Jintropin produces typical side effects associated with high purity somatropin. These side effects range from requirement to take afternoon “baby” naps, carpal tunnel syndrome, water retention, morning aches and hypoglycemia.

Jintropin has 191 amino acid residues and a molecular weight of about 22,125 daltons. The amino acid sequence of the product is identical to that of human growth hormone of pituitary origin. Jintropin is synthesized in a strain of Escherichia coli that has been modified by the addition of the gene for human growth hormone.

Jintropin is a sterile, white, lyophilized powder intended for subcutaneous or intramuscular administration after reconstitution. Jintropin is a highly purified preparation. Phosphoric acid and/or sodium hydroxide may have been added to adjust the pH. Reconstituted solutions have a pH of approximately 7.5. This product is oxygen sensitive.

VIAL--Each vial of Jintropin contains 5 mg Jintropin (15 IU or 225 nanomoles); 25 mg mannitol; 5 mg glycine; and 1.13 mg dibasic sodium phosphate. Each vial is supplied in a combination package with an accompanying 5-mL vial of diluting solution. The diluent contains water for injection with 0.3% Metacresol as a preservative and 1.7% glycerin.

CARTRIDGE--The cartridges of Jintropin contain either 6 mg (18 IU), 12 mg (36 IU), or 24 mg (72 IU) of somatropin. The 6 mg, 12 mg and 24 mg cartridges contain respectively: mannitol 18 mg, 36 mg, and 72 mg; glycine 6 mg, 12 mg, and 24 mg; dibasic sodium phosphate 1.36 mg, 2.72 mg, and 5.43 mg. Each cartridge is supplied in a combination package with an accompanying syringe containing approximately 3 mL of diluting solution. The diluent contains Water for Injection; 0.3% Metacresol as a preservative; and 1.7%, 0.29%, and 0.29% gylcerin in the 6 mg, 12 mg, and 24 mg cartridges respectively.

CLINICAL PHARMACOLOGY

General: Linear Growth --Jintropin stimulates linear growth in pediatric patients who lack adequate normal endogenous growth hormone. In vitro, preclinical, and clinical testing have demonstrated that Jintropin is therapeutically equivalent to human growth hormone of pituitary origin and achieves equivalent pharmacokinetic profiles in normal adults. Treatment of growth hormone-deficient pediatric patients and patients with Turner syndrome with Jintropin produces increased growth rate and IGF-I(Insulin-like Growth Factor-I/Somatomedin-C) concentrations similar to those seen after therapy with human growth hormone of pituitary origin.

In addition, the following actions have been demonstrated for Jintropin and/or human growth hormone of pituitary origin.

Tissue Growth --

1. Skeletal Growth: Jintropin stimulates skeletal growth in pediatric patients with growth hormone deficiency. The measurable increase in body length after administration of either Jintropin or human growth hormone of pituitary origin results from an effect on the growth plates of long bones. Concentrations of IGF-I, which may play a role in skeletal growth, are low in the serum of growth hormone-deficient pediatric patients but increase during treatment with Somatropin. Elevations in mean serum alkaline phosphatase concentrations are also seen.

2. Cell Growth: It has been shown that there are fewer skeletal muscle cells in short-statured pediatric patients who lack endogenous growth hormone as compared with normal pediatric populations. Treatment with human growth hormone of pituitary origin results in an increase in both the number and size of muscle cells.

Protein Metabolism --Linear growth is facilitated in part by increased cellular protein synthesis. Nitrogen retention, as demonstrated by decreased urinary nitrogen excretion and serum urea nitrogen, follows the initiation of therapy with human growth hormone of pituitary origin. Treatment with Jintropin results in a similar decrease in serum urea nitrogen.

Carbohydrate Metabolism --Pediatric patients with hypopituitarism sometimes experience fasting hypoglycemia that is improved by treatment with Somatropin. Large doses of human growth hormone may impair glucose tolerance. Untreated patients with Turner syndrome have an increased incidence of glucose intolerance. Administration of human growth hormone to normal adults or patients with Turner syndrome resulted in increases in mean serum fasting and postprandial insulin levels although mean values remained in the normal range. In addition, mean fasting and postprandial glucose and hemoglobin A 1C levels remained in the normal range.

Lipid Metabolism --In growth hormone-deficient patients, administration of human growth hormone of pituitary origin has resulted in lipid mobilization, reduction in body fat stores, and increased plasma fatty acids.

Mineral Metabolism --Retention of sodium, potassium, and phosphorus is induced by human growth hormone of pituitary origin. Serum concentrations of inorganic phosphate increased in patients with growth hormone deficiency after therapy with Jintropin or human growth hormone of pituitary origin. Serum calcium is not significantly altered in patients treated with either human growth hormone of pituitary origin or Somatropin.

PHARMACOKINETICS Absorption --Jintropin has been studied following intramuscular, subcutaneous, and intravenous administration in adult volunteers. The absolute bioavailability of Jintropin is 75% and 63% after subcutaneous and intramuscular administration, respectively.

Distribution --The volume of distribution of Jintropin after intravenous injection is about 0.07 L/kg.

Metabolism --Extensive metabolism studies have not been conducted. The metabolic fate of Jintropin involves classical protein catabolism in both the liver and kidneys. In renal cells, at least a portion of the breakdown products of growth hormone is returned to the systemic circulation. In normal volunteers, mean clearance is 0.14 L/hr/kg. The mean half-life of intravenous Jintropin is 0.36 hours, whereas subcutaneously and intramuscularly administered Jintropin have mean half-lives of 3.8 and 4.9 hours, respectively. The longer half-life observed after subcutaneous or intramuscular administration is due to slow absorption from the injection site.

Excretion --Urinary excretion of intact Jintropin has not been measured. Small amounts of Jintropin have been detected in the urine of pediatric patients following replacement therapy.

Special Populations

Geriatric --The pharmacokinetics of Jintropin has not been studied in patients greater than 60 years of age.

Pediatric --The pharmacokinetics of Jintropin in pediatric patients is similar to adults.

Gender --No studies have been performed with Somatropin. The available literature indicates that the pharmacokinetics of growth hormone is similar in both men and women.

Race --No data are available.

Renal, Hepatic insufficiency --No studies have been performed with Somatropin.

INDICATIONS AND USAGE

Pediatric Patients --Jintropin is indicated for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of normal endogenous growth hormone.

Jintropin is indicated for the treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed.

Adult Patients --Jintropin is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet both of the following two criteria:

Adult Onset: Patients who have growth hormone deficiency either alone or with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma;

or

Childhood Onset: Patients who were growth hormone-deficient during childhood who have growth hormone deficiency confirmed as an adult before replacement therapy with Jintropin is started.

and

Biochemical diagnosis of growth hormone deficiency, by means of a negative response to a standard growth hormone stimulation test [maximum peak < 5 ng/mL when measured by RIA (polyclonal antibody) or < 2.5 ng/mL when measured by IRMA (monoclonal antibody)].

CONTRAINDICATIONS

Jintropin should not be used for growth promotion in pediatric patients with closed epiphyses.

Jintropin should not be used or should be discontinued when there is any evidence of active malignancy. Anti-malignancy treatment must be complete with evidence of remission prior to the institution of therapy.

Jintropin should not be reconstituted with the supplied Diluent for Jintropin for use by patients with a known sensitivity to either Melacresol or glycerin.

Growth hormone should not be initiated to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or to patients having acute respiratory failure. Two placebo-controlled clinical trials in non-growth hormone deficient adult patients (n=522) with these conditions revealed a significant increase in mortality (41.9% vs. 19.3%) among Jintropin treated patients (doses 5.3-8 mg/day) compared to those receiving placebo (see WARNINGS ).

WARNING

If sensitivity to the diluent should occur the vials may be reconstituted with Bacteriostatic Water for Injection, USP or, Sterile Water for Injection, USP. When Jintropin is used with Bacteriostatic Water (Benzyl Alcohol preserved), the solution should be kept refrigerated at 2° to 8°C (36° to 46°F) and used within 14 days. Benzyl alcohol as a preservative in Bacteriostatic Water for Injection, USP has been associated with toxicity in newborns. When administering Jintropin to newborns, use the Jintropin diluent provided or if the patient is sensitive to the diluent, use Sterile Water for Injection, USP. When Jintropin is reconstituted with Sterile Water for Injection, USP in this manner, use only one dose per Jintropin vial and discard the unused portion. If the solution is not used immediately, it must be refrigerated (2° to 8°C [36° to 46°F]) and used within 24 hours.

Cartridges should be reconstituted only with the supplied diluent. Cartridges should not be reconstituted with the Diluent for Jintropin provided with Jintropin Vials, or with any other solution. Cartridges should not be used if the patient is allergic to Metacresol or glycerin.

See CONTRAINDICATIONS for information on increased mortality in patients with acute critical illnesses in intensive care units due to complications following open heart or abdominal surgery, multiple accidental trauma or with acute respiratory failure. The safety of continuing growth hormone treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. Therefore, the potential benefit of treatment continuation with growth hormone in patients having acute critical illnesses should be weighed against the potential risk.

PRECAUTIONS

General --Therapy with Jintropin should be directed by physicians who are experienced in the diagnosis and management of patients with growth hormone deficiency, Turner syndrome or adult patients with either childhood-onset or adult-onset growth hormone deficiency.

Patients with preexisting tumors or with growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process. In pediatric patients, clinical literature has demonstrated no relationship between Jintropin replacement therapy and CNS tumor recurrence. In adults, it is unknown whether there is any relationship between Jintropin replacement therapy and CNS tumor recurrence.

Patients should be monitored carefully for any malignant transformation of skin lesions.

For patients with diabetes mellitus, the insulin dose may require adjustment when Jintropin therapy is instituted. Because human growth hormone may induce a state of insulin resistance, patients should be observed for evidence of glucose intolerance. Patients with diabetes or glucose intolerance should be monitored closely during Jintropin therapy.

In patients with hypopituitarism (multiple hormonal deficiencies) standard hormonal replacement therapy should be monitored closely when Jintropin therapy is administered. Hypothyroidism may develop during treatment with somatropin, and inadequate treatment of hypothyroidism may prevent optimal response to somatropin.

Pediatric Patients ( see General Precautions) --Pediatric patients with endocrine disorders, including growth hormone deficiency, may develop slipped capital epiphyses more frequently. Any pediatric patient with the onset of a limp during growth hormone therapy should be evaluated.

Growth hormone has not been shown to increase the incidence of scoliosis. Progression of scoliosis can occur in children who experience rapid growth. Because growth hormone increases growth rate, patients with a history of scoliosis who are treated with growth hormone should be monitored for progression of scoliosis. Skeletal abnormalities including scoliosis are commonly seen in untreated Turner syndrome patients.

Patients with Turner syndrome should be evaluated carefully for otitis media and other ear disorders since these patients have an increased risk of ear or hearing disorders (see Adverse Reactions). Patients with Turner syndrome are at risk for cardiovascular disorders (e.g. stroke, aortic aneurysm, hypertension) and these conditions should be monitored closely.

Patients with Turner syndrome have an inherently increased risk of developing autoimmune thyroid disease. Therefore, patients should have periodic thyroid function tests and be treated as indicated ( see General Precautions ).

Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea and/or vomiting has been reported in a small number of pediatric patients treated with growth hormone products. Symptoms usually occurred within the first eight (8) weeks of the initiation of growth hormone therapy. In all reported cases, IH-associated signs and symptoms resolved after termination of therapy or a reduction of the growth hormone dose. Funduscopic examination of patients is recommended at the initiation and periodically during the course of growth hormone therapy. Patients with Turner syndrome may be at increased risk for development of IH.

Adult Patients (see General Precautions )--Patients with epiphyseal closure who were treated with growth hormone replacement therapy in childhood should be re-evaluated according to the criteria in INDICATIONS AND USAGE before continuation of Jintropin therapy at the reduced dose level recommended for growth hormone-deficient adults.

Experience in patients above 60 years is lacking.

Experience with prolonged treatment in adults is limited.

Drug Interactions --Excessive glucocorticoid therapy may prevent optimal response to somatropin. If glucocorticoid replacement therapy is required, the glucocorticoid dosage and compliance should be monitored carefully to avoid either adrenal insufficiency or inhibition of growth promoting effects.

Limited published data indicate that growth hormone (GH) treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). Careful monitoring is advisable when GH is administered in combination with other drugs known to be metabolized by CP450 liver enzymes.

Carcinogenesis, Mutagenesis, Impairment of Fertility --Long-term animal studies for carcinogenicity and impairment of fertility with this human growth hormone (Somatropin) have not been performed. There has been no evidence to date of Somatropin-induced mutagenicity.

Pregnancy--Pregnancy Category C --Animal reproduction studies have not been conducted with Somatropin. It is not known whether Jintropin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Jintropin should be given to a pregnant woman only if clearly needed.

Nursing Mothers --There have been no studies conducted with Jintropin in nursing mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Jintropin is administered to a nursing woman.

Information for Patients --Patients being treated with growth hormone and/or their parents should be informed of the potential risks and benefits associated with treatment. Instructions on appropriate use should be given, including a review of the contents of the patient information insert. This information is intended to aid in the safe and effective administration of the medication. It is not a disclosure of all possible adverse or intended effects.

Patients and/or parents should be thoroughly instructed in the importance of proper needle disposal. A puncture resistant container should be used for the disposal of used needles and/or syringes (consistent with applicable state requirements). Needles and syringes must not be reused ( see Information for Patient insert).

ADVERSE REACTIONS

Growth-Hormone Deficient Pediatric Patients- - As with all protein pharmaceuticals, a small percentage of patients may develop antibodies to the protein. During the first six months of Jintropin therapy in 314 naive patients, only 1.6% developed specific antibodies to Jintropin (binding capacity >/= 0.02 mg/L). None had antibody concentrations which exceeded 2 mg/L. Throughout 8 years of this same study, 2 patients (0.6%) had binding capacity >2 mg/L. Neither patient demonstrated a decrease in growth velocity at or near the time of increased antibody production. It has been reported that growth attenuation from pituitary-derived growth hormone may occur when antibody concentrations are >1.5 mg/L.

In addition to an evaluation of compliance with the treatment program and of thyroid status, testing for antibodies to human growth hormone should be carried out in any patient who fails to respond to therapy.

In studies with growth hormone-deficient pediatric patients, injection site pain was reported infrequently. A mild and transient edema, which appeared in 2.5% of patients, was observed early during the course of treatment.

Leukemia has been reported in a small number of pediatric patients who have been treated with growth hormone, including growth hormone of pituitary origin as well as of recombinant DNA origin (somatrem and somatropin). The relationship, if any, between leukemia and growth hormone therapy is uncertain.

Turner Syndrome Patients -- In a randomized, concurrent controlled trial, there was a statistically significant increase, in the occurrence of otitis media (43% vs 26%), ear disorders (18% vs 5%) and surgical procedures (45% vs 27%) in patients receiving Jintropin compared with untreated control patients. Other adverse events of special interest to Turner syndrome patients were not significantly different between treatment groups . A similar increase in otitis media was observed in an 18 month placebo-controlled trial.

OVERDOSAGE

Acute overdosage could lead initially to hypoglycemia and subsequently to hyperglycemia. Long-term overdosage could result in signs and symptoms of gigantism/acromegaly consistent with the known effects of excess human growth hormone. (See recommended and maximal dosage instructions given below.)

DOSAGE AND ADMINISTRATION

Pediatric Patients- - The Jintropin dosage and administration schedule should be individualized for each patient. Therapy should not be continued if epiphyseal fusion has occurred. Response to growth hormone therapy tends to decrease with time. However, failure to increase growth rate, particularly during the first year of therapy, should prompt close assessment of compliance and evaluation of other causes of growth failure such as hypothyroidism, under-nutrition and advanced bone age.

Growth hormone-deficient pediatric patients --The recommended weekly dosage is 0.18 mg/kg (0.54 IU/kg) of body weight. The maximal replacement weekly dosage is 0.3 mg/kg (0.90 IU/kg) of body weight. It should be divided into equal doses given either on 3 alternate days, 6 times per week or daily. The subcutaneous route of administration is preferable; intramuscular injection is also acceptable. The dosage and administration schedule for Jintropin should be individualized for each patient.

Turner Syndrome --A weekly dosage of up to 0.375 mg/kg (1.125 IU/kg) of body weight administered by subcutaneous injection is recommended. It should be divided into equal doses given either daily or on 3 alternate days.

Adult Patients--

Growth hormone-deficient adult patients --The recommended dosage at the start of therapy is not more than 0.006 mg/kg/day (0.018 IU/kg/day) given as a daily subcutaneous injection. The dose may be increased according to individual patient requirements to a maximum of 0.0125 mg/kg/day (0.0375 IU/kg/day).

During therapy, dosage should be titrated if required by the occurrence of side effects or to maintain the IGF-I response below the upper limit of normal IGF-I levels, matched for age and sex. To minimize the occurrence of adverse events in patients with increasing age or excessive body weight, dose reductions may be necessary.

Reconstitution --

Vial--Each 5-mg vial of Jintropin should be reconstituted with 1.5 to 5 mL of Diluent for Somatropin. The diluent should be injected into the vial of Jintropin by aiming the stream of liquid against the glass wall. Following reconstitution, the vial should be swirled with a GENTLE rotary motion until the contents are completely dissolved. DO NOT SHAKE. The resulting solution should be inspected for clarity. It should be clear. If the solution is cloudy or contains particulate matter, the contents MUST NOT be injected.

Before and after injection, the septum of the vial should be wiped with rubbing alcohol or an alcoholic antiseptic solution to prevent contamination of the contents by repeated needle insertions. Sterile disposable syringes and needles should be used for administration of Somatropin. The volume of the syringe should be small enough so that the prescribed dose can be withdrawn from the vial with reasonable accuracy.

Cartridge--Each cartridge of Jintropin should only be reconstituted using the diluent syringe and the diluent connector which accompany the cartridge and should not be reconstituted with the Diluent for Jintropin provided with Jintropin vials. (See WARNINGS section). See the Somatropinn™ User Guide for comprehensive directions on Jintropin cartridge reconstitution.

The reconstituted solution should be inspected for clarity. It should be clear. If the solution is cloudy or contains particulate matter, the contents MUST NOT be injected.

The Somatropinn™ allows the sumatropin dosage volume to be dialed in increments of 0.048 mL per click of dosage knob, and the maximum dosage volume that can be injected is 0.576 mL (based on a 12 click maximum). (See Table 7 for additional information).

STABILITY AND STORAGE

Vials--Before Reconstitution --Vials of Jintropin and Diluent for Jintropin are stable when refrigerated (2° to 8°C [36° to 46°F]). Avoid freezing Diluent for Somatropin. Expiration dates are stated on the labels.

If OVERDOSE is suspected

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

Consumer information use

• If your symptoms or health problems do not get better or if they become worse, call your doctor.

• Do not share your drugs with others and do not take anyone else's drugs.

• Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.

• Throw away unused or expired drugs. Do not flush down a toilet or pour down a drain unless you are told to do so. Check with your pharmacist if you have questions about the best way to throw out drugs. There may be drug take-back programs in your area.

• Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about nandrolone, please talk with your doctor, nurse, pharmacist, or other health care provider.

• If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened

Warnings

PELIOSIS HEPATIS, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION, BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER FAILURE. THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING LIVER FAILURE OR INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS. LIVER CELL TUMORS ARE ALSO REPORTED. MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN-DEPENDENT, BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED. WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR. HOWEVER, HEPATIC TUMORS ASSOCIATED WITH ANDROGENS OR ANABOLIC STEROIDS ARE MUCH MORE VASCULAR THAN OTHER HEPATIC TUMORS AND MAY BE SILENT UNTIL LIFE-THREATENING INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. BLOOD LIPID CHANGES THAT ARE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF ATHEROSCLEROSIS ARE SEEN IN PATIENTS TREATED WITH ANDROGENS AND ANABOLIC STEROIDS. THESE CHANGES INCLUDE DECREASED HIGH-DENSITY LIPOPROTEIN AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEIN. THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE.

How do I store and/or throw out?

If you need to store it at home, talk with your doctor, nurse, or pharmacist about how to store it.

PROTECT FROM LIGHT. Store in carton until contents are used.

ATTENTION: All these products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human and veterinary purposes.